Clinical Trial: A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07144163) titled 'A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia' on Aug. 20.

Brief Summary: The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: Congenital Adrenal Hyperplasia Classic Congenital Adrenal Hyperplasia

Intervention: DRUG: Atumelnant

Atumelnant, tablets, once daily by mouth

DRUG: Placebo

Placebo, tablets, once daily by mouth

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Crinetics Pharmaceuticals Inc.

Disclaimer: Curated by HT Syndication....